Bronchogen
Also known as
Short peptide studied for pulmonary and tissue recovery applications. Preliminary evidence — investigational stage with limited published human data.
Evidence
Animal or in-vitro only
Risk band
Known AEs, monitoring advised
Research goals
Summary
Bronchogen (Ala-Glu-Asp-Leu, also written Ala-Asp-Glu-Leu) is a short synthetic peptide studied almost entirely at the molecular and cell-culture level, not as a clinically validated therapeutic [1,3]. Biophysical studies show it acts as a DNA-stabilizing agent, modestly raising DNA melting temperature, and that it binds preferentially to certain CNG/CTG nucleotide sequences and can penetrate the nucleus in HeLa cells [1,4]. In cell cultures it tissue-specifically stimulated expression of differentiation markers in bronchial epithelial cells and, more broadly, short peptides of this class modulated growth- and differentiation-related gene expression [2,3]. The available evidence is in-vitro and mechanistic only; there are no interventional human trials demonstrating clinical benefit, so its therapeutic value remains preliminary and unestablished.
Sources
- 1. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability Bulletin of experimental biology and medicine, 2011.
- 2. Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum Biochemistry. Biokhimiia, 2017.
- 3. Peptides tissue-specifically stimulate cell differentiation during their aging Bulletin of experimental biology and medicine, 2012.
- 4. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Biochemistry. Biokhimiia, 2011.
For educational purposes only.